Stem Cell Transplant denials: 41.1% overturned by independent reviewers
In 56 California IMR decisions from 2002 to 2023, reviewers overturned the plan 23 times (41.1%). In the last five years: 33.3% of 6. Denials reach IMR only when a member appeals all the way; read the caveats below before generalising.
By diagnosis
| Diagnosis category | Decisions | Overturned | Last 5 years |
|---|---|---|---|
| Cancer | 18 | 44.4% | — |
| CNS/ Neuromusc Dis | 15 | 33.3% | 66.7% of 3 |
| Immuno Disorders | 7 | 85.7% | — |
| Orth/Musculoskeletal | 5 | 0.0% | 0.0% of 3 |
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 3 | 0.0% |
| 2023 | 3 | 66.7% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 22 | 31.8% | 41.1% |
| Experimental or investigationalThe findings discuss whether the treatment is experimental. | 16 | 50.0% | 41.1% |
| Prior therapies failedThe findings mention treatments that were tried without adequate response. | 4 | 50.0% | 41.1% |
| FDA approval or off-label use discussedThe findings discuss the FDA label status of the treatment. | 4 | 25.0% | 41.1% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 3 | 0.0% | 41.1% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for a stem cell transplant. Multiple sclerosis (MS) is an incurable disease which can be ameliorated by therapies that inhibit the immune attack against the myelin that coats neuronal axons. There is strong evidence supporting autologous and allogeneic hematopoietic stem cell transplant (HSCT) in autoimmune diseases like MS. …”
“Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for autologous hematopoietic stem cell transplantation (aHSCT) and bone marrow harvesting for transplantation. Based on the current peer-reviewed medical literature, the requested aHSCT is supported as likely to be more beneficial for treatment of this patient than any available standard therapy. The patient presents with a history of …”
“Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for stem cell treatment for her multiple sclerosis (MS). Findings: The physician reviewer found that review of the submitted documentation and relevant literature demonstrates the medical necessity of the requested services. Hematopoietic stem cell transplantation (HSCT) is well-established in the peer-reviewed literature as the most potent therapy in …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Stem Cell Transplant denials overturned?
In 56 California IMR decisions from 2002 to 2023, reviewers overturned the plan 23 times (41.1%). In the last five years: 33.3% of 6.
What did the reviewers' findings mention in overturned cases?
The table on this page counts keyword matches in the findings: prior therapies tried, contraindications, guidelines cited, published evidence, whether the records supported the request. They describe what the findings say, not why the case was decided.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but the reasoning is the same kind: criteria, documentation and alternatives. Use the findings as a guide to what to document.
Related: California appeal rights · California external-review reversal rate · The levers library · CSV
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.